Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis

1.0kCitations
Citations of this article
308Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The US National Cancer Institute alert in February, 1999, stated that concomitant chemotherapy and radiotherapy should be considered for all patients with cervical cancer. Our aim was to review the effects of chemoradiotherapy on overall and progression-free survival, local and distant control, and acute and late toxicity in patients with cervical cancer. Methods: With the methodology of the Cochrane Collaboration, we did a systematic review of all known randomised controlled trials done between 1981 and 2000 (17 published, two unpublished) of chemoradiation for cervical cancer. Findings: The trials included 4580 randomised patients, and 2865-3611 patients (62-78%) were available for analysis. Cisplatin was the most common agent used. The findings suggest that chemoradiation improves overall survival (hazard ratio 0.71, p<0.0001), whether platinum was used (0.70, p<0.0001) or not (0.81, p=0.20). A greater beneficial effect was seen in trials that included a high proportion of stage I and II patients (p=0.009). An improvement in progression-free survival was also seen with chemoradiation (0.61, p<0.0001). Thus, the absolute benefit in progression-free and overall survival was 16% (95% CI 13-19) and 12% (8-16), respectively. A significant benefit of chemoradiation on both local (odds ratio 0.61, p<0.0001) and distant recurrence (0.57, p<0.0001) was also recorded. Grade 3 or 4 haematological (odds ratio 1.49-8.60) and gastrointestinal (2.22) toxicities were significantly greater in the concomitant chemoradiation group than the control group. There was insufficient data to establish whether late toxicity was increased in the concomitant chemoradiation group. Interpretation: Concomitant chemotherapy and radiotherapy improves overall and progression-free survival and reduces local and distant recurrence in selected patients with cervical cancer, which may give a cytotoxic and sensitisation effect.

References Powered by Scopus

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

4065Citations
N/AReaders
Get full text

Beta blockade during and after myocardial infarction: An overview of the randomized trials

2786Citations
N/AReaders
Get full text

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

2381Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cervical cancer

873Citations
N/AReaders
Get full text

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials

800Citations
N/AReaders
Get full text

The cervical cancer epidemic that screening has prevented in the UK

665Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Green, J. A., Kirwan, J. M., Tierney, J. F., Symonds, P., Fresco, L., Collingwood, M., & Williams, C. J. (2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet, 358(9284), 781–786. https://doi.org/10.1016/S0140-6736(01)05965-7

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 125

64%

Researcher 39

20%

Professor / Associate Prof. 19

10%

Lecturer / Post doc 13

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 155

82%

Agricultural and Biological Sciences 12

6%

Nursing and Health Professions 11

6%

Biochemistry, Genetics and Molecular Bi... 11

6%

Save time finding and organizing research with Mendeley

Sign up for free